Fact Check: The '1 in 5 Americans on GLP-1s' Headline
The '1 in 5 Americans on GLP-1s' headline is wrong. Here's what the actual survey and claims data show about GLP-1 usage prevalence in 2026.
"One in five Americans is now on a GLP-1" is one of the most widely repeated statistics of the 2025-2026 GLP-1 conversation. It shows up in news headlines, podcast talking points, investor presentations, and policy debates. It is also, on close examination, not quite what it sounds like.
The actual survey data, properly interpreted, shows a more nuanced picture: roughly 12-15% of U.S. adults report having ever tried a GLP-1 medication (for any purpose), and the share currently on active therapy is lower. The "1 in 5" headline most often originates from a KFF Health Tracking Poll number that combined past and current users across all indications.
Where the "1 in 5" Number Comes From
The KFF Health Tracking Poll series has measured public awareness and use of GLP-1 medications since 2023. One specific poll found that approximately 1 in 8 U.S. adults had ever used a GLP-1 medication for any purpose, with higher percentages in certain demographic subgroups. Subsequent press coverage conflated several different measures — ever-used, currently using, awareness, household-level exposure — and the "1 in 5" figure emerged from one of those conflations.
The difference between "ever tried" and "currently on therapy" is substantial. GLP-1 discontinuation rates are high. Published data from commercial pharmacy claims suggests roughly half of patients discontinue within one year, for reasons ranging from cost to side effects to weight-loss plateau to insurance changes.
What the Better Data Actually Shows
| Measure | Approximate Share of U.S. Adults |
|---|---|
| Ever used a GLP-1 (any indication) | 12-15% |
| Currently using a GLP-1 (any indication) | 8-12% |
| Currently using for weight loss specifically | 5-8% |
| Currently using for type 2 diabetes | 3-5% |
| Aware of GLP-1 medications | 80%+ |
Exact numbers vary by survey methodology, year, and population. The KFF polls, Trilliant Health claims analyses, and IQVIA prescription data all triangulate in roughly the same range. No credible source supports "1 in 5 currently using."
Affordable direct-care marketplace — book a consultation with a licensed clinician for FDA-approved brand-name GLP-1 medications.
Brand-name · Insurance-friendly
Comprehensive GLP-1 weight management with licensed providers, labs, and home delivery.
Full-service GLP-1 program
Medical weight-management platform with oral and injectable GLP-1 options and clinical oversight.
Oral & injectable options
Why the Headline Went Viral Anyway
The GLP-1 class is legitimately one of the fastest-growing drug categories in modern U.S. history. Prescription volume roughly tripled between 2022 and 2024, and awareness is extremely high. "One in five Americans on GLP-1s" captures the cultural moment more than the statistical reality — it's a reasonable approximation of how present the category feels, even if the actual patient numbers are lower.
The distinction matters for policy analysis, investor modeling, and clinical planning. A world in which 20% of adults are active GLP-1 users looks very different from a world in which 10% are active and another 5% have tried and discontinued. Total market size, Medicare cost projections, and supply-chain capacity assumptions all depend on the accurate number.
The More Interesting Data
More useful than the overall "how many Americans" number is the demographic breakdown. GLP-1 use skews strongly toward adults with higher body-mass index, adults with type 2 diabetes, adults with commercial insurance coverage for weight-management medications, and adults aged 40-65. It skews female for weight-management use and roughly neutral for diabetes use. Geographic distribution correlates with commercial telehealth market penetration and with state-level Medicaid coverage policies.
For a single headline number that captures the phenomenon accurately, "tens of millions of Americans have used a GLP-1" is defensible. "One in five currently using" is not.
The '1 in 5 Americans on GLP-1s' headline overstates current usage by roughly 2x. The real number for active current users is closer to 1 in 10, with discontinuation rates high enough that the 'ever tried' number is meaningfully different from the 'currently on' number.
Sourcing Your Own Facts
For readers who want to source their own statistics on GLP-1 usage, the most reliable publicly available sources are KFF Health Tracking Polls (released roughly quarterly), CDC/NHANES survey data (released annually), IQVIA MIDAS prescription data (requires subscription, but some summaries are published), and CMS Medicare Part D utilization data (freely available, but lags by several quarters). Each source has its own methodology and limitations, and the careful approach is to triangulate across several rather than cite a single headline. See our related reporting on employer health plan coverage trends and Novo vs. Lilly revenue forecasts.
Sources
- Kaiser Family Foundation. KFF Health Tracking Poll — GLP-1 usage series. www.kff.org
- Trilliant Health. GLP-1 prescription trend analyses. www.trillianthealth.com
- CDC. National Health and Nutrition Examination Survey (NHANES). www.cdc.gov
- CMS. Medicare Part D drug utilization dashboard. www.cms.gov
- IQVIA. MIDAS global prescription data overview. www.iqvia.com
Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.